Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2026 08:00 ET | Source: Galecto, Inc.

Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

-- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis...
March 04, 2026 08:00 ET | Source: Galecto, Inc.

Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that it granted...
March 02, 2026 08:00 ET | Source: Galecto, Inc.

Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company working to redefine care for people with hematologic disorders, today announced that company...
February 12, 2026 16:01 ET | Source: Galecto, Inc.

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...
February 10, 2026 22:42 ET | Source: Galecto, Inc.

Galecto Announces Pricing of $275 Million Underwritten Public Offering

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...
February 10, 2026 16:04 ET | Source: Galecto, Inc.

Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with...
January 12, 2026 08:00 ET | Source: Galecto, Inc.

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human...
January 06, 2026 08:00 ET | Source: Galecto, Inc.

Galecto Announces Key Additions to Leadership Team

Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially...
December 16, 2025 17:00 ET | Source: Galecto, Inc.

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock...
November 10, 2025 07:00 ET | Source: Galecto, Inc.

Galecto Announces Acquisition of Damora Therapeutics

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with...